Coupled with the milestone discovery relating to the use of circulating anti-nephrin autoantibodies in proteinuric glomerulopathies (Figure 2), these findings can form the foundation for future research into an alternative causative mechanism of podocytopathy in DN, which could potentially revolutionize our insights into its treatment approach. This evidence concerns the gene NPHS1 and liver dysplastic nodule.